Table 3– Resistance to anti-tuberculosis (TB) agents at the initiation of treatment: 1,027 multidrug-resistant (MDR)-TB cases stratified by non-extensively drug-resistant (XDR)-TB and XDR-TB status, Latvia, 2000–2004#
ResistanceNon-XDR-TBXDR-TBp-valueTotal
Cases n979481027
First-line drugs
 Streptomycin929 (94.9)47 (97.9)0.34976 (95.0)
 Pyrazinamide662 (67.6)43 (89.6)0.001705 (68.7)
 Ethambutol596 (60.9)38 (79.2)0.01634 (61.7)
Second-line drugs
 Kanamycin396 (40.5)41 (85.4)<0.001437 (42.6)
 Capreomycin223 (22.8)27 (56.3)<0.001250 (24.3)
 Ofloxacin18 (1.8)48 (100)<0.00166 (6.4)
 Prothionamide238 (24.3)24 (50.0)<0.001262 (25.5)
 PAS267 (27.3)14 (29.2)0.77281 (27.4)
 Thiacetazone130 (13.3)9 (18.8)0.27139 (13.5)
 Cycloserine18 (1.8)2 (4.2)0.2520 (2.0)
  • Data are presented as n or n (%). PAS: para-aminosalicylic acid. #: year 2000 for civilians only.